Glucose-insulin-potassium infusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction

ISRCTN ISRCTN56720616
DOI https://doi.org/10.1186/ISRCTN56720616
Secondary identifying numbers 99.028
Submission date
17/05/2005
Registration date
20/05/2005
Last edited
15/02/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Felix Zijlstra
Scientific

Hanzeplein 1
Groningen
30.001
Netherlands

Phone +31 (0)503612355
Email f.zijlstra@thorax.umcg.nl

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Scientific title
Study acronymGlucose-Insulin-Potassium Study (GIPS)
Study objectivesIn this study we considered the question of whether adjunction of glucose-insulin-potassium (GIK) infusion to primary coronary transluminal angioplasty (PTCA) is effective in patients with an acute myocardial infarction (MI).
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedST elevation myocardial infarction (mi)
InterventionAfter admission, patients were randomly assigned to either glucose-insulin-potassium (GIK) infusion or no infusion. In patients randomized to GIK, a continuous infusion of 80 mmol potassium chloride in 500 ml 20% glucose with a rate of 3 ml/kg body weight/hour over an 8- to 12-hour period in a peripheral venous line was given, as soon as possible. A continuous infusion of short-acting insulin (50 U Actrapid) in 50 ml 0.9% sodiumchloride was started. Baseline insulin-infusion dose and hourly adjustments of the insulin dose were based on an algorithm to obtain blood-glucose levels between 7.0 and 11.0 mmol/l.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)glucose-insulin-potassium
Primary outcome measure30-day mortality
Secondary outcome measuresRecurrent infarction, repeat coronary angioplasty, and the composite incidence of death, recurrent infarction, or repeat coronary angioplasty.
Overall study start date01/04/1998
Completion date30/09/2001

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants940
Key inclusion criteriaAll consecutive patients with symptoms consistent with acute MI of >30 min duration, presenting within 24 hours after the onset of symptoms and with an ST-segment elevation of more than 1 mm (0.1 mV) in two or more contiguous leads on the electrocardiogram, or new onset left bundle branch block, were evaluated for inclusion in this single-center study. Patients presented at our center and patients referred for treatment of high-risk myocardial infarction (MI) from nine referring hospitals without angioplasty facilities were included.
Key exclusion criteriaPatients were excluded when pre-treated with thrombolysis or when an illness associated with a marked restricted life expectancy was present.
Date of first enrolment01/04/1998
Date of final enrolment30/09/2001

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Hanzeplein 1
Groningen
30.001
Netherlands

Sponsor information

Netherlands Heart Foundation (Netherlands)
Charity

Bordewijklaan 3
The Hague
300
Netherlands

Phone +31 (0)703155555
Email info@hartstichting.nl
Website http://www.hartstichting.nl/go/
ROR logo "ROR" https://ror.org/05nxhgm70

Funders

Funder type

Charity

Netherlands Heart Foundation (99.028)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 02/06/2005 Yes No